Simon Lord

Affiliations: 
2010-2014 University of Oxford, Oxford, United Kingdom 
Google:
"Simon Lord"

Parents

Sign in to add mentor
Adrian L Harris grad student 2010-2014 Oxford

Children

Sign in to add trainee
Benjamin Harris grad student 2018-2021 Oxford
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Scott NP, Teoh EJ, Flight H, et al. (2021) Characterising F-fluciclovine uptake in breast cancer through the use of dynamic PET/CT imaging. British Journal of Cancer
Baird RD, Linossi C, Middleton M, et al. (2020) First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2000596
Di Giovannantonio M, Harris BH, Zhang P, et al. (2020) Heritable genetic variants in key cancer genes link cancer risk with anthropometric traits. Journal of Medical Genetics
Lord SR, Collins JM, Cheng WC, et al. (2019) Transcriptomic analysis of human primary breast cancer identifies fatty acid oxidation as a target for metformin. British Journal of Cancer
Banerji U, van Herpen CML, Saura C, et al. (2019) Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. The Lancet. Oncology
Morotti M, Bridges E, Valli A, et al. (2019) Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer. Proceedings of the National Academy of Sciences of the United States of America
Lord SR, Cheng WC, Liu D, et al. (2018) Integrated Pharmacodynamic Analysis Identifies Two Metabolic Adaption Pathways to Metformin in Breast Cancer. Cell Metabolism
Morotti M, Dass PH, Harris AL, et al. (2017) Pharmacodynamic and Pharmacokinetic Markers For Anti-angiogenic Cancer Therapy: Implications for Dosing and Selection of Patients. European Journal of Drug Metabolism and Pharmacokinetics
Mehta S, Hughes NP, Li S, et al. (2016) Radiogenomics Monitoring in Breast Cancer Identifies Metabolism and Immune Checkpoints as Early Actionable Mechanisms of Resistance to Anti-angiogenic Treatment. Ebiomedicine
Lord S, Funes JM, Harris AL, et al. (2016) Antiangiogenic resistance and cancer metabolism: opportunities for synthetic lethality. Current Drug Targets
See more...